G.Barekat Pharm (XTEH:BRKT1) EPS (Basic): IRR (TTM As of Mar. 2017)


What is G.Barekat Pharm EPS (Basic)?

G.Barekat Pharm XTEH:BRKT1 EPS (Basic) is IRR as of Mar. 2017.

G.Barekat Pharm's basic earnings per share (Basic EPS) for the six months ended in Mar. 2017 was IRR191.36. G.Barekat Pharm does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2017.

G.Barekat Pharm's EPS (Diluted) for the six months ended in Mar. 2017 was IRR191.36. G.Barekat Pharm does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017.

G.Barekat Pharm's EPS without NRI for the six months ended in Mar. 2017 was IRR4.70. G.Barekat Pharm does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2017.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

G.Barekat Pharm  (XTEH:BRKT1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

G.Barekat Pharm EPS (Basic) Related Terms

G.Barekat Pharm EPS (Basic) Historical Data

* Premium members only.

The historical data trend for G.Barekat Pharm's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

G.Barekat Pharm EPS (Basic) Chart

G.Barekat Pharm Annual Data
Trend Mar16 Mar17
EPS (Basic)
123.59 191.36

G.Barekat Pharm Semi-Annual Data
Mar16 Mar17
EPS (Basic) 123.59 191.36

G.Barekat Pharm EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

G.Barekat Pharm's Basic EPS for the fiscal year that ended in Mar. 2017 is calculated as

Basic EPS (A: Mar. 2017 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1044706-0)/5459.311
=191.36

G.Barekat Pharm's Basic EPS for the quarter that ended in Mar. 2017 is calculated as

Basic EPS (Q: Mar. 2017 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1044706-0)/5459.311
=191.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of IRR mean?
G.Barekat Pharm (XTEH:BRKT1) has a EPS (Basic) of IRR as of Mar. 2017. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on G.Barekat Pharm and its competitors.
Is G.Barekat Pharm's EPS (Basic) too high?
G.Barekat Pharm's current EPS (Basic) is IRR.
How does G.Barekat Pharm's EPS (Basic) compare to PRGBQ and PZRXQ?
G.Barekat Pharm's EPS (Basic) of IRR can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on G.Barekat Pharm and its competitors. G.Barekat Pharm's current EPS (Basic) is IRR. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is G.Barekat Pharm stock overvalued right now?
G.Barekat Pharm (XTEH:BRKT1) has a current EPS (Basic) of IRR. The current EPS (Basic) is IRR. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For G.Barekat Pharm (XTEH:BRKT1), the current EPS (Basic) is IRR as of Mar. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

G.Barekat Pharm Business Description

Address No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.